{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:55:32Z","timestamp":1787622932721,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold>There is lack of national studies that assess the risks associated with the drugs provided under the Brazilian public health system for treating Alzheimer\u2019s disease. Then, this study determined the prevalence and severity of self-reported adverse drug reactions (ADRs) prescribed to patients with Alzheimer\u2019s disease in the Brazilian public health system.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>A cross-sectional study was carried out based on public data from the MEDEX system (information on dispensing data, known as exceptional dispensing medications) and interviews with patients and\/or caregivers who get access to Alzheimer\u2019s drugs at a public pharmacy in a large Brazilian city, between July and September 2017, inquiring about ADRs and serious adverse events (SAEs).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>The subjects were asked about ADRs and SAEs related to the use of donepezil, galantamine, rivastigmine and memantine. Out of 285 patients enrolled on the database, 250 participated in the study (87.7%). Among the participants, approximately 63.0% were female, 70.3% aged \u226575 years and 70.3% had comorbidities. Overall, 209 patients (83.6%) reported at least one ADR (total 1,149 ADRs) and rivastigmine was associated with the largest number of ADRs per patient (7.9 ADRs\/patient). The predominant adverse effects were psychiatric disorders with common frequency (57.1%) and mild severity (89.0%). Six patients (2.4%) had SAEs that required hospitalization. The use of antipsychotics was the variable associated with ADR (OR = 4.95; 95% CI: 1.45\u201316.93;<jats:italic>p<\/jats:italic>= 0.011).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold>There was a large number of reported ADRs and most of them were of common frequency and mild severity, being mainly related to psychiatric disorders. Considering the fragility of these patients, it is important to improve safety-related care in the use of drugs for treating this disease.<\/jats:p>","DOI":"10.3389\/fphar.2020.538095","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T19:54:31Z","timestamp":1610308471000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Frequency and Severity of Adverse Drug Reactions to Medications Prescribed for Alzheimer\u2019s Disease in a Brazilian City: Cross-Sectional Study"],"prefix":"10.3389","volume":"11","author":[{"given":"T\u00e2nia Regina","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciane Cruz","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane de C\u00e0ssia","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0144337","DOI":"10.1371\/journal.pone.0144337","article-title":"Adverse effects of cholinesterase inhibitors in dementia, according to the pharmacovigilance databases of the United-States and Canada","volume":"10","author":"Ali","year":"2015","journal-title":"PLoS One"},{"key":"B2","first-page":"857","article-title":"Caracter\u00edsticas de idosos acometidos pela doen\u00e7a de Alzheimer e seus familiares cuidadores principais","volume":"14","author":"Barros De Matos","year":"2012","journal-title":"Rev. Eletr\u00f4nica Enferm."},{"key":"B3","unstructured":"Alzheimer\u2019s dementia. The right clinical information, right where it\u2019s needed2019"},{"key":"B4","article-title":"Minist\u00e9rio da Sa\u00fade. Secretaria Executiva. Sistema \u00danico de Sa\u00fade (SUS): princ\u00edpios e conquistas","year":"2000"},{"key":"B5","unstructured":"Minist\u00e9rio da Sa\u00fade. Portaria n\u00ba 1554, de 30 de julho de 2013. Disp\u00f5e sobre as regras de financiamento e execu\u00e7\u00e3o do Componente Especializado da Assist\u00eancia Farmac\u00eautica no \u00e2mbito do Sistema \u00danico de Sa\u00fade (SUS). Di\u00e1rio Oficial da Uni\u00e3o, n\u00b0 146 31 julho 2013, Se\u00e7\u00e3o I, p\u00e1gina 69. Alterada pela Portaria GM\/MS no 1996 11 setembro 2013, publicada no Di\u00e1rio Oficial da Uni\u00e3o n\u00b0 177 12 setembro 2013, Se\u00e7\u00e3o I, p\u00e1gina 372013"},{"key":"B6","unstructured":"Minist\u00e9rio da Sa\u00fade. Portaria conjunta n\u00ba 13, de 28 de novembro de 2017 aprova o protocolo cl\u00ednico e diretrizes terap\u00eauticas da doen\u00e7a de Alzheimer2017"},{"key":"B7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/bcp.12596","article-title":"Adverse drug reactions in special populations - the elderly","volume":"80","author":"Davies","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1590\/S1516-31802011000100009","article-title":"Prevalence of dementia among older adults Brazilians: a systematic review","volume":"129","author":"Fagundes","year":"2011","journal-title":"Sao Paulo Med. J."},{"key":"B9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1590\/S0101-60832009000400003","article-title":"Rea\u00e7\u00f5es adversas causadas por f\u00e1rmacos que atuam no sistema nervoso: an\u00e1lise de registros de um centro de farmacovigil\u00e2ncia do Brasil","volume":"36","author":"Fonteles","year":"2009","journal-title":"Arch. Clin. Psychiatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1017\/S1041610213000859","article-title":"Association between behavioral and psychological symptoms and psychotropic drug use among old people with cognitive impairment living in geriatric care settings","volume":"25","author":"Gustafsson","year":"2013","journal-title":"Int. Psychogeriatr."},{"key":"B11","unstructured":"Cidades, Brasil, S\u00e3o Paulo, Sorocaba2018"},{"key":"B12","unstructured":"Proje\u00e7\u00e3o da popula\u00e7\u00e3o do Brasil e das Unidades da Federa\u00e7\u00e3o2019"},{"key":"B13","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016 \/ S1474-4422 (08) 70169-8","article-title":"Alzheimer\u2019s disease and vascular dementia in developing countries: prevalence, management, and risk factors","volume":"7","author":"Kalaria","year":"2008","journal-title":"Lancet Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1177\/1060028015602274","article-title":"Adverse drug reactions reported with cholinesterase inhibitors: an analysis of 16 years of individual case safety reports from VigiBase","volume":"49","author":"Kr\u00f6ger","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/pds.3471","article-title":"Adverse drug reactions in patients with Alzheimer\u2019s disease and related dementia in France: a national multicentre cross-sectional study","volume":"22","author":"Laroche","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1517\/14740338.2014.942219","article-title":"Patient reports of the frequency and severity of adverse reactions associated with biological agents prescribed for psoriasis in Brazil","volume":"13","author":"Lopes","year":"2014","journal-title":"Expet Opin. Drug Saf."},{"key":"B17","first-page":"29","article-title":"Comparing therapeutic benefit and risk","volume":"54","author":"Meyboom","year":"1999","journal-title":"Therapie"},{"key":"B18","unstructured":"Guidelines. Dementia: assessment, management and support for people living with dementia and their careers2018"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B20","first-page":"2268","article-title":"Factors associated with preventable adverse drug reactions","volume":"51","author":"Pearson","year":"1994","journal-title":"Am. J. Hosp. Pharm."},{"key":"B21","doi-asserted-by":"publisher","first-page":"63. e2","DOI":"10.1016 \/ j.jalz.2012.11.00710","article-title":"The global prevalence of dementia: a systematic review and metaanalysis","volume":"9","author":"Prince","year":"2013","journal-title":"Alzheimers Dement."},{"key":"B22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/2050-6511-15-32","article-title":"Self-reported adverse drug reactions and their influence on highly active antiretroviral therapy in HIV infected patients: a cross sectional study","volume":"15","author":"Tadesse","year":"2014","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/JAD-132690","article-title":"Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheime\u2019s disease: a systematic review and meta-analysis","volume":"41","author":"Tan","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.2165\/00002018-200730110-00005","article-title":"Drug interactions with cholinesterase inhibitors","volume":"30","author":"Tavassoli","year":"2007","journal-title":"Drug Saf."},{"key":"B25","unstructured":"Interna\u00e7\u00f5es hospitalares por Rea\u00e7\u00f5es Adversas a Medicamentos (RAM) em um hospital de ensino VaralloF. R. MastroianniP. C. PlanetaC. S. 2010"},{"key":"B26","unstructured":"The World health Organization\u2019s (the \u201cWHO\u201d) global database for ADRs, maintained by the Uppsala monitoring centre (the \u201cUMC\u201d)2018"},{"key":"B27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2296-9-35","article-title":"Mix of methods is needed to identify adverse events in general practice: a prospective observational study","volume":"9","author":"Wetzels","year":"2008","journal-title":"BMC Fam. Pract."},{"key":"B28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/ S1474-4422(16)00062-4","article-title":"Defeating Alzheimer\u2019s disease and other dementias: a priority for European science and society","volume":"15","author":"Winblad","year":"2016","journal-title":"Lancet Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1097\/MLR.0b013e31822047a8","article-title":"Can we rely on patients\u2019 reports of adverse events?","volume":"49","author":"Zhu","year":"2011","journal-title":"Med. Care"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.538095\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T03:03:11Z","timestamp":1618801391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.538095\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":29,"alternative-id":["10.3389\/fphar.2020.538095"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.538095","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,15]]},"article-number":"538095"}}